Increased benefit in terms of tumor inhibition was also obtained by measures that down-regulated CCR1 or CCL5 activities, combined with ICBs directed to PD-1 or PD-L1; here again, major roles were revealed for TAMs and MDSCs as targets whose inhibition potentiates the activities of ICBs (126, 127). This evidence concerns the gene CD274 and neoplasm.